SBIR Phase I: Dense Nanolipid Fluids (DNLFs) for Delivery of Drugs with Poor Bioavailability: Synthesis, Manufacture, and Drug Properties

SBIR 第一阶段：用于递送生物利用度较差的药物的致密纳米脂质流体 (DNLF)：合成、制造和药物特性

• 批准号: 2212222
• 负责人: Eric Morrison
• 金额: $ 25.6万
• 依托单位: SUPERIOR NANO LLC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-06-15 至 2023-05-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2212222&HistoricalAwards=false
• 关键词: SBIR; Phase; Dense; Nanolipid; Fluids

The broader impact /commercial potential of this Small Business Innovation Research (SBIR) Phase I project is to care for patients suffering from diseases including diabetes, multiple Sclerosis (MS), acquired immunodeficiency syndrome (AIDS), and cancer using nano dosage forms of drug molecules. Making drugs nano-sized helps them be absorbed and move to parts of the body where needed. The ability to manufacture nanosized drugs comes from the discovery that drug sizes may be decreased with a twin screw extruder, a type of machine usually used to produce bulk products such as plastic pipes, garbage bags, snack foods, cereal, and pasta. Before the discovery of the twin screw extruder, drug nanoparticles were only made in thimbleful quantities and were prohibitively expensive. This NSF SBIR Phase I project seeks to tap the potential of nano-sized drug forms by allowing them to be made economically and getting them into the hands of medical researchers. This Small Business Innovation Research (SBIR) Phase I project seeks to provide new knowledge related to surfactant-lipid-water systems and drug delivery nanoparticles. Although there has been much research focused on increasing the body’s absorption of drugs using lipid nanoparticles, translation to the clinic has been limited because nanoparticles cannot be produced with sufficient reproducibility, quality, or in sufficient quantities, making them prohibitively expensive. This SBIR project seeks to solve these problems by using twin-screw extrusion, a process typically used for bulk manufacturing of commodity goods such as plastic pipes, garbage bags, snack foods and pasta. The twin screw extruder process is based on the transient formation of rupturable surfactant-lipid-water mesophases during transit through the extruder barrel. To be successful at the twin screw extrusion of drug nano dosage forms, new scientific knowledge must be created to advance conceptualization of surfactant-lipid-water systems from time invariant equilibrium structures to highly time dependent dynamic non-equilibrium processes.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这个小企业创新研究（SBIR）第一阶段项目的更广泛的影响/商业潜力是使用药物分子的纳米剂型来护理患有糖尿病、多发性硬化症（MS）、获得性免疫缺陷综合征（AIDS）和癌症等疾病的患者。将药物制成纳米尺寸有助于它们被吸收并移动到身体需要的部位。制造纳米药物的能力来自于发现药物尺寸可以用双螺杆挤出机减小，双螺杆挤出机是一种通常用于生产散装产品的机器，如塑料管，垃圾袋，零食，谷物和面食。在双螺杆挤出机被发现之前，药物纳米颗粒的产量非常少，而且价格昂贵。NSF SBIR第一阶段项目旨在通过经济地制造纳米药物并将其交给医学研究人员来挖掘纳米药物的潜力。这个小企业创新研究（SBIR）第一阶段项目旨在提供与表面活性剂-脂质-水系统和药物递送纳米颗粒相关的新知识。虽然已经有很多研究集中在使用脂质纳米颗粒增加身体对药物的吸收，但转化到临床上受到限制，因为纳米颗粒不能以足够的再现性、质量或足够的数量生产，使得它们过于昂贵。该SBIR项目旨在通过使用双螺杆挤出来解决这些问题，双螺杆挤出是一种通常用于大宗商品生产的工艺，如塑料管，垃圾袋，零食和面食。双螺杆挤出机工艺是基于在通过挤出机机筒的运输过程中瞬时形成可破裂的表面活性剂-脂质-水中间相。为了在药物纳米剂型的双螺杆挤出中取得成功，必须创造新的科学知识，以将表面活性剂-脂质-水系统的概念化从时不变的平衡结构推进到高度时变的动态非平衡过程。该奖项反映了NSF的法定使命，并被认为值得通过使用基金会的知识价值和更广泛的影响审查标准进行评估来支持。